Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
SM Mangsbo, LC Sandin, K Anger… - Journal of …, 2010 - journals.lww.com
Tumor immunotherapy aims to break effector T-cell anergy and to block suppressive cell
types and ligands allowing effector cells to exert tumor eradication. Previous reports
demonstrate that cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibodies promote T-
cell activation and render T effector cells resistant to T regulatory cells (Tregs) whereas
programmed death receptor-1 (PD-1)/PD-L1 blockade results in loss of peripheral tolerance.
Herein, we explored single or combined antibody blockade of CTLA-4 and PD-1 alone or …
types and ligands allowing effector cells to exert tumor eradication. Previous reports
demonstrate that cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibodies promote T-
cell activation and render T effector cells resistant to T regulatory cells (Tregs) whereas
programmed death receptor-1 (PD-1)/PD-L1 blockade results in loss of peripheral tolerance.
Herein, we explored single or combined antibody blockade of CTLA-4 and PD-1 alone or …